Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats

EGFR controls bone development by negatively regulating mTOR-signaling during osteoblast differentiation

(2018) Markus Linder et al.   CELL DEATH AND DIFFERENTIATION

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

(2016) Penella Woll   Therapeutics and Clinical Risk Management

Osteoblast-specific overexpression of amphiregulin leads to transient increase in femoral cancellous bone mass in mice

(2015) Mithila Vaidya et al.   BONE

Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats

(2015) Chiaming Fan et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

(2015) Sara A Hurvitz et al.   LANCET ONCOLOGY

Changes in Bone Density after Cancer Treatment in Patients with Cervical and Endometrial Cancer

(2015) Young Lim Oh et al.   Journal of Cancer

Methotrexate-Induced Bone Marrow Adiposity Is Mitigated by Folinic Acid Supplementation Through the Regulation of Wnt/β-Catenin Signalling

(2014) Kristen R. Georgiou et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Potential roles of metallothioneins I and II in protecting bone growth following acute methotrexate chemotherapy

(2014) Chiaming Fan et al.   JOURNAL OF CHEMOTHERAPY

Bone mineral density at diagnosis determines fracture rate in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocol

(2013) Mariël L. te Winkel et al.   BONE

Epidermal Growth Factor Receptor (EGFR) Signaling Promotes Proliferation and Survival in Osteoprogenitors by Increasing Early Growth Response 2 (EGR2) Expression

(2013) Abhishek Chandra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer

(2013) Zhongzhen Guan et al.   JOURNAL OF CLINICAL ONCOLOGY

Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss

(2012) Rethi Raghu Nadhanan et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Attenuated Wnt/β-catenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats

(2012) Kristen R. Georgiou et al.   BONE

Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea

(2012) Joanne M. Bowen et al.   CANCER BIOLOGY & THERAPY

The Critical Role of the Epidermal Growth Factor Receptor in Endochondral Ossification

(2011) Xianrong Zhang et al.   JOURNAL OF BONE AND MINERAL RESEARCH

EGFR signaling suppresses osteoblast differentiation and inhibits expression of master osteoblastic transcription factors Runx2 and osterix

(2011) Ji Zhu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Methotrexate chemotherapy reduces osteogenesis but increases adipogenic potential in the bone marrow

(2011) Kristen R. Georgiou et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Imatinib for Chronic Myeloid Leukemia: The Impact of Its Effectiveness and Long-term Side Effects

(2011) B. D. Smith   JNCI-Journal of the National Cancer Institute

Epidermal growth factor receptor plays an anabolic role in bone metabolism in vivo

(2010) Xianrong Zhang et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair

(2008) Carmen E. Macsai et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling

(2008) TacGhee Yi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

(2008) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

(2008) Q. Ryan et al.   ONCOLOGIST